View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 8, 2020

Mapi’s Jerusalem facility to produce Covid-19 vaccines to boost supply

Israeli biopharma company Mapi Pharma has decided to commission its manufacturing facility to help support the supply of Covid-19 vaccines to the country, as well as the European Union (EU) and other internationalmarkets.

Israeli biopharma company Mapi Pharma has decided to commission its manufacturing facility to help support the supply of Covid-19 vaccines to the country, as well as the European Union (EU) and other international markets.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The GMP-approved facility, audited by the Israeli health ministry and set up at Jerusalem Har-Hotzim technology park, has the potential to deliver a reliable supply of Covid-19 vaccines if approved, Mapi said.

Originally built by Johnson & Johnson (J&J) to supply sterile products, Mapi’s Jerusalem Fill & Finish facility gathered more than $100m in investment.

Currently, Mapi is working on a new line for sterile filling and finishing of liquids and powders for injections at the facility.

Furthermore, cold-chain and storage capacities will also be available for the vaccine delivery to Israel and the EU.

Mapi Pharma chairman and CEO Ehud Marom said: “The global supply chain of vaccinations is currently limited and requires agility to enable the supply of vaccines on a broad scale.

“By making our manufacturing capacity available, we hope to assist in the quick deployment of vaccines once they are approved by the health authorities. We are in communications with the major vaccination developers and governments to join forces in the fight against this dangerous virus.”

Israeli health ministry approvals are also recognised by the EU, which exempts Israeli manufacturers from conducting lab tests on shipments from Israel to Europe.

In a separate development, Kindred Biosciences, via its subsidiary Centaur Biopharmaceutical Services, has expanded an agreement with Vaxart for the manufacture of the latter’s oral vaccine against Covid-19 and other vaccine candidates.

Under the deal, Centaur’s plant in California, US will bolster the production of Covid-19 clinical trial material into mid-size bioreactors while its Kansas plant will manufacture at 2000l scale in its single-use bioreactors.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology